Advertisement


Hyo Sook Han, MD, on Metastatic Breast Cancer: Trial Results on Veliparib, Carboplatin, and Paclitaxel

2016 San Antonio Breast Cancer Symposium

Advertisement

Hyo Sook Han, MD, of Moffitt Cancer Center, discusses phase II study findings on the efficacy and tolerability of veliparib in combination with carboplatin and paclitaxel vs placebo in patients with BRCA1 or BRCA2 mutations and metastatic breast cancer (Abstract S2-05).



Related Videos

Breast Cancer

Jame Abraham, MD, on ER-Positive Breast Cancer: Expert Perspective on Initial Results of NRG Oncology/NSABP B-42

Jame Abraham, MD, of the Cleveland Clinic, gives his perspective on study results of extended adjuvant endocrine therapy in postmenopausal women with estrogen receptor–positive breast cancer who have completed previous adjuvant endocrine treatment (Abstract S1-05).

Breast Cancer

Sonja Vliek, MD, and Sabine Linn, MD, PhD, on Early Breast Cancer: Results of the TEAM IIb Trial

Sabine Linn, MD, PhD, and Sonja Vliek, MD, both of the Netherlands Cancer Institute, discuss study findings on adjuvant ibandronate in postmenopausal women with early breast cancer (Abstract S6-02).

Breast Cancer

Stephen R.D. Johnston, MBBS, PhD, and Ann H. Partridge, MD, on Breast Cancer: Managing Metastatic ER+ Disease

Stephen R.D. Johnston, MBBS, PhD, of The Royal Marsden NHS Foundation Trust, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss the role of endocrine therapy and optimal sequencing, recent progress in first-line treatment, and resistance pathways and second-line treatment (Plenary Lecture 1).

Cost of Care
Global Cancer Care
Breast Cancer

Peter Bach, MD, on The Global Cost of Cancer Care

Peter Bach, MD, of Memorial Sloan Kettering Cancer Center, summarizes his plenary lecture on drug costs and their effect on the affordability of cancer care worldwide (Plenary Lecture 3).

Breast Cancer

Diana M. Eccles, MD, on Young Breast Cancer Patients: Results From the POSH Study

Diana M. Eccles, MD, of the University of Southampton, discusses findings from a study of sporadic and hereditary breast cancer and whether BRCA status affects outcome in young breast cancer patients (Abstract S2-03).

Advertisement

Advertisement




Advertisement